Nicole G. Campos
Research Subjects
Nicole G. Campos has a total of 274 co-authors. Here are the top co-authors by number of shared publications:
- Mark Schiffman
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland
17 shared publications - Amy Berrington de González
Division of Genetics and Epidemiology, The Institute of Cancer Research , London
15 shared publications - John T. Schiller
Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
15 shared publications - Meredith S. Shiels
Division of Cancer Epidemiology and Genetics, National Cancer Institute , Rockville, MD
15 shared publications - Neal D. Freedman
Division of Cancer Control and Population Sciences, National Cancer Institute , Rockville, MD
15 shared publications - Stanley Lipkowitz
Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
15 shared publications
Latest Publications
- Open Access
- 6 March 2026
- Published by SAGE Publications in Medical Decision Making
- Vol. 46 (5) , 591-600
Adapting Sexual Behavior Survey Data to Parameterize an Agent-Based Model of Human Papillomavirus (HPV) Transmission
Purpose: Sexual transmission of human papillomavirus (HPV) infection is important for capturing the indirect effects of interventions in mathematical models, but limited data create challenges for reflecting sexual behavior patterns over the lifespan of individuals and across heterogenous populations. We used nationally representative data from the United States to parameterize, calibrate, and validate a heterosexual transmission model of HPV. Methods: Based on sexual behavior data from the National Survey of Family Growth (2011–2019), we categorized respondents into 4 sexual activity categories, using their percentile of cumulative lifetime partners compared with others within their same sex and age group. We modeled probabilistic partnership acquisition and dissolution by age, sex, and sexual activity category. Partnership data were incorporated into an existing agent-based model of HPV transmission in the United States. We calibrated 1) per-partnership HPV transmission and 2) reduced risk of type-specific reinfection from natural immunity to fit age- and type-specific HPV prevalence using the National Health and Nutrition Examination Survey (NHANES 2002–2008). We validated the final model by comparing model-based projections of HPV prevalence against empirical data in the US population before and after widespread HPV vaccination. Results: After calibrating to fit overall HPV prevalence, model validation exercises indicated that the distribution of prevaccine HPV prevalence across sexual activity categories closely matched NHANES estimates. Simulating vaccination rates over 10 y, the model replicated postvaccine NHANES data for prevalence of HPV16. Conclusion: Capturing HPV transmission dynamics requires an understanding of sexual behavior across populations and over time. Defining sexual activity categories based on cumulative lifetime partners can capture patterns of HPV risk over a lifespan to reflect the dynamics of HPV transmission and vaccination. Highlights: Using data from a large national survey, we developed sexual behavior inputs for an agent-based model of HPV transmission. We define 4 heterogenous risk groups using cumulative lifetime sexual behavior for males and females and find we can recreate validation data on both lifetime sexual patterns and age-specific HPV prevalence. Our calibrated model also reproduces early patterns of HPV reduction following HPV vaccine introduction. Modelers seeking to understand the long-term effects of the HPV vaccine should carefully consider the heterogeneity of sexual behavior across groups as well as changes in behavior over the lifespan.
- 6 March 2026
- Published by SAGE Publications in Medical Decision Making
- Vol. 46 (5) , 591-600
Open AccessAdapting Sexual Behavior Survey Data to Parameterize an Agent-Based Model of Human Papillomavirus (HPV) Transmission
Purpose: Sexual transmission of human papillomavirus (HPV) infection is important for capturing the indirect effects of interventions in mathematical models, but limited data create challenges for reflecting sexual behavior patterns over the lifespan of individuals and across heterogenous populations. We used nationally representative data from the United States to parameterize, calibrate, and validate a heterosexual transmission model of HPV. Methods: Based on sexual behavior data from the National Survey of Family Growth (2011–2019), we categorized respondents into 4 sexual activity categories, using their percentile of cumulative lifetime partners compared with others within their same sex and age group. We modeled probabilistic partnership acquisition and dissolution by age, sex, and sexual activity category. Partnership data were incorporated into an existing agent-based model of HPV transmission in the United States. We calibrated 1) per-partnership HPV transmission and 2) reduced risk of type-specific reinfection from natural immunity to fit age- and type-specific HPV prevalence using the National Health and Nutrition Examination Survey (NHANES 2002–2008). We validated the final model by comparing model-based projections of HPV prevalence against empirical data in the US population before and after widespread HPV vaccination. Results: After calibrating to fit overall HPV prevalence, model validation exercises indicated that the distribution of prevaccine HPV prevalence across sexual activity categories closely matched NHANES estimates. Simulating vaccination rates over 10 y, the model replicated postvaccine NHANES data for prevalence of HPV16. Conclusion: Capturing HPV transmission dynamics requires an understanding of sexual behavior across populations and over time. Defining sexual activity categories based on cumulative lifetime partners can capture patterns of HPV risk over a lifespan to reflect the dynamics of HPV transmission and vaccination. Highlights: Using data from a large national survey, we developed sexual behavior inputs for an agent-based model of HPV transmission. We define 4 heterogenous risk groups using cumulative lifetime sexual behavior for males and females and find we can recreate validation data on both lifetime sexual patterns and age-specific HPV prevalence. Our calibrated model also reproduces early patterns of HPV reduction following HPV vaccine introduction. Modelers seeking to understand the long-term effects of the HPV vaccine should carefully consider the heterogeneity of sexual behavior across groups as well as changes in behavior over the lifespan.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S11 and Figure S1 from Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047
Supplemental Table 1. 15 leading causes of cancer death in the U.S. in 2019. Supplemental table 2. Trends in total cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 3. Trends in lung cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 4. Trends in colorectal cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 5. Trends in pancreatic cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 6. Trends in female breast cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 7. Trends in prostate cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 8. Trends in liver/IHBD cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 9. Trends in cancer mortality rates in the U.S., 2000-2019 for selected sites. Supplemental Table 10. US breast cancer incidence-based mortality*. Supplemental Table 11. U.S. breast cancer incidence-based mortality by age at death. Supplemental Figure 1. Liver cancer incidence (1992-2019), survival (2000-2019) and mortality (2000-2019 projected through 2047). This figure excludes cases of intrahepatic bile duct cancer.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S11 and Figure S1 from Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047
Supplemental Table 1. 15 leading causes of cancer death in the U.S. in 2019. Supplemental table 2. Trends in total cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 3. Trends in lung cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 4. Trends in colorectal cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 5. Trends in pancreatic cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 6. Trends in female breast cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 7. Trends in prostate cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 8. Trends in liver/IHBD cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 9. Trends in cancer mortality rates in the U.S., 2000-2019 for selected sites. Supplemental Table 10. US breast cancer incidence-based mortality*. Supplemental Table 11. U.S. breast cancer incidence-based mortality by age at death. Supplemental Figure 1. Liver cancer incidence (1992-2019), survival (2000-2019) and mortality (2000-2019 projected through 2047). This figure excludes cases of intrahepatic bile duct cancer.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047
On February 2, 2022, President Biden and First Lady Dr. Biden reignited the Cancer Moonshot, setting a new goal to reduce age-standardized cancer mortality rates by at least 50% over the next 25 years in the United States. We estimated trends in U.S. cancer mortality during 2000 to 2019 for all cancers and the six leading types (lung, colorectum, pancreas, breast, prostate, liver). Cancer death rates overall declined by 1.4% per year from 2000 to 2015, accelerating to 2.3% per year during 2016 to 2019, driven by strong declines in lung cancer mortality (−4.7%/year, 2014 to 2019). Recent declines in colorectal (−2.0%/year, 2010–2019) and breast cancer death rates (−1.2%/year, 2013–2019) also contributed. However, trends for other cancer types were less promising. To achieve the Moonshot goal, progress against lung, colorectal, and breast cancer deaths needs to be maintained and/or accelerated, and new strategies for prostate, liver, pancreatic, and other cancers are needed. We reviewed opportunities to prevent, detect, and treat these common cancers that could further reduce population-level cancer death rates and also reduce disparities.Significance:We reviewed opportunities to prevent, detect, and treat common cancers, and show that to achieve the Moonshot goal, progress against lung, colorectal, and breast cancer deaths needs to be maintained and/or accelerated, and new strategies for prostate, liver, pancreatic, and other cancers are needed.See related commentary by Bertagnolli et al., p. 1049.This article is highlighted in the In This Issue feature, p. 1027
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047
On February 2, 2022, President Biden and First Lady Dr. Biden reignited the Cancer Moonshot, setting a new goal to reduce age-standardized cancer mortality rates by at least 50% over the next 25 years in the United States. We estimated trends in U.S. cancer mortality during 2000 to 2019 for all cancers and the six leading types (lung, colorectum, pancreas, breast, prostate, liver). Cancer death rates overall declined by 1.4% per year from 2000 to 2015, accelerating to 2.3% per year during 2016 to 2019, driven by strong declines in lung cancer mortality (−4.7%/year, 2014 to 2019). Recent declines in colorectal (−2.0%/year, 2010–2019) and breast cancer death rates (−1.2%/year, 2013–2019) also contributed. However, trends for other cancer types were less promising. To achieve the Moonshot goal, progress against lung, colorectal, and breast cancer deaths needs to be maintained and/or accelerated, and new strategies for prostate, liver, pancreatic, and other cancers are needed. We reviewed opportunities to prevent, detect, and treat these common cancers that could further reduce population-level cancer death rates and also reduce disparities.Significance:We reviewed opportunities to prevent, detect, and treat common cancers, and show that to achieve the Moonshot goal, progress against lung, colorectal, and breast cancer deaths needs to be maintained and/or accelerated, and new strategies for prostate, liver, pancreatic, and other cancers are needed.See related commentary by Bertagnolli et al., p. 1049.This article is highlighted in the In This Issue feature, p. 1027
- 14 November 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (4) , 735-744
IPVS Consensus Statement on The Natural History of Cervical Human Papillomavirus Infection
Background: Changes in cervical type-specific human papillomavirus (HPV) detection may reflect both natural variation in detectability and recent infection or clearance. Methods: The Policy Committee of the International Papillomavirus Society (IPVS) convened a multidisciplinary working group to review scientific evidence and terminology related to the natural history of cervical type-specific HPV infections. Results: The group proposes an updated model that distinguishes 3 cervical states: no HPV infection, undetectable HPV infection, and detectable HPV infection. An undetectable HPV infection refers to either a state of low viral genome load below the cutoff of the assay used or to a particular state of viral latency. These 2 states are virtually indistinguishable, and viral latency remains a topic of ongoing research and debate. The transition from HPV not detected to HPV detected is consistent with several possible events, including (i) acquisition from a partner, (ii) autoinoculation, (iii) transition from undetected to detected HPV infection, and (iv) transient deposition of viral material. Conversely, the transition from HPV detected to HPV not detected is consistent with (i) viral clearance, (ii) transition from detected to undetected HPV infection, and (iii) inadequate sampling. The likelihood of each possible explanation depends on context, including screening history, exposure, age, and immune status. Conclusions: By distinguishing true cervical states from observed test results, the updated model acknowledges uncertainties that complicate the interpretation of HPV test result patterns in research and practice. Adopting this model may improve clarity and ensure consistency in scientific and clinical communication about cervical HPV infections.
- 14 November 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (4) , 735-744
IPVS Consensus Statement on The Natural History of Cervical Human Papillomavirus Infection
Background: Changes in cervical type-specific human papillomavirus (HPV) detection may reflect both natural variation in detectability and recent infection or clearance. Methods: The Policy Committee of the International Papillomavirus Society (IPVS) convened a multidisciplinary working group to review scientific evidence and terminology related to the natural history of cervical type-specific HPV infections. Results: The group proposes an updated model that distinguishes 3 cervical states: no HPV infection, undetectable HPV infection, and detectable HPV infection. An undetectable HPV infection refers to either a state of low viral genome load below the cutoff of the assay used or to a particular state of viral latency. These 2 states are virtually indistinguishable, and viral latency remains a topic of ongoing research and debate. The transition from HPV not detected to HPV detected is consistent with several possible events, including (i) acquisition from a partner, (ii) autoinoculation, (iii) transition from undetected to detected HPV infection, and (iv) transient deposition of viral material. Conversely, the transition from HPV detected to HPV not detected is consistent with (i) viral clearance, (ii) transition from detected to undetected HPV infection, and (iii) inadequate sampling. The likelihood of each possible explanation depends on context, including screening history, exposure, age, and immune status. Conclusions: By distinguishing true cervical states from observed test results, the updated model acknowledges uncertainties that complicate the interpretation of HPV test result patterns in research and practice. Adopting this model may improve clarity and ensure consistency in scientific and clinical communication about cervical HPV infections.
- 18 March 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (10) , 2124-2129
Initial evaluation of a new cervical screening strategy combining human papillomavirus genotyping and automated visual evaluation: the Human Papillomavirus–Automated Visual Evaluation Consortium
The HPV-Automated Visual Evaluation Consortium is validating a cervical screening strategy enabling accurate cervical screening in resource-limited settings. A rapid, low-cost human papillomavirus (HPV) assay permits sensitive HPV testing of self-collected vaginal specimens; HPV-negative women are reassured. Triage of positive participants combines HPV genotyping (4 groups in order of cancer risk) and visual inspection assisted by automated cervical visual evaluation that classifies cervical appearance as severe, indeterminate, or normal. Together, the combination predicts which women have precancer, permitting targeted management to those most needing treatment. We analyzed CIN3+ yield for each HPV-Automated Visual Evaluation risk level (HPV genotype crossed by automated cervical visual evaluation classification) from 9 clinical sites (Brazil, Cambodia, Dominican Republic, El Salvador, Eswatini, Honduras, Malawi, Nigeria, and Tanzania). Data from 1832 HPV-positive participants confirmed that HPV genotype and automated cervical visual evaluation classification strongly and independently predict risk of histologic CIN3+. The combination of these low-cost tests provided excellent risk stratification, warranting pre-implementation demonstration projects.
- 18 March 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (10) , 2124-2129
Initial evaluation of a new cervical screening strategy combining human papillomavirus genotyping and automated visual evaluation: the Human Papillomavirus–Automated Visual Evaluation Consortium
The HPV-Automated Visual Evaluation Consortium is validating a cervical screening strategy enabling accurate cervical screening in resource-limited settings. A rapid, low-cost human papillomavirus (HPV) assay permits sensitive HPV testing of self-collected vaginal specimens; HPV-negative women are reassured. Triage of positive participants combines HPV genotyping (4 groups in order of cancer risk) and visual inspection assisted by automated cervical visual evaluation that classifies cervical appearance as severe, indeterminate, or normal. Together, the combination predicts which women have precancer, permitting targeted management to those most needing treatment. We analyzed CIN3+ yield for each HPV-Automated Visual Evaluation risk level (HPV genotype crossed by automated cervical visual evaluation classification) from 9 clinical sites (Brazil, Cambodia, Dominican Republic, El Salvador, Eswatini, Honduras, Malawi, Nigeria, and Tanzania). Data from 1832 HPV-positive participants confirmed that HPV genotype and automated cervical visual evaluation classification strongly and independently predict risk of histologic CIN3+. The combination of these low-cost tests provided excellent risk stratification, warranting pre-implementation demonstration projects.
- 6 February 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (6) , 1209-1217
Impact of screening for human papillomavirus-positive oropharyngeal cancers: a microsimulation-based modeling study
Background: We estimated the impact of screening on morbidity and mortality of human papillomavirus (HPV)16-positive oropharyngeal cancer among US men aged 45-79 years. Methods: We developed an individual-level, state-transition natural history microsimulation model to estimate the impact of screening using oral HPV16 detection, HPV16-E6 antibody detection, and transcervical ultrasound of neck/oropharynx. We compared clinical detection to counterfactual screen detection for cancer stage, single- vs multiple-modality treatment, and survival. Screening scenarios encompassed 4 progression speeds across cancer stages (very slow, slow, fast, and very fast) and 4 screening frequencies. Results: Among US men aged 45-79 years in 2021 (n = 54 881 311), 163 958 clinically diagnosed human papillomavirus (HPV)-positive oropharyngeal cancers and 32 009 deaths would occur through age 84 in the absence of screening. Assuming very-fast progression, 4%, 20%, 31%, and 60% of these cancers would be detected by one-off, 5-yearly, 3-yearly, and annual screening. Annual screening (very-fast progression) could reduce the number of cancers diagnosed at advanced stages (American Joint Committee on Cancer, 7th edition, stages III/IV: 90.0% with no screening vs 59.1%) and treated by multiple modalities (80.6% with no screening vs 50.6%). Cancer mortality would also be reduced by 36.2%, with a gain of 106 000 life-years. Annual screening would have a number needed to screen (NNS) of 561 per screen-detected cancer, 1118 per additional cancer treated by single modality, 4740 per death prevented, and 520 per life-year gained; such high NNS reflect potential inefficiency of population-level screening. Conclusions: If proven efficacious in randomized trials and cost-effective, screening for HPV-positive oropharyngeal cancers could provide considerable population-level reductions in advanced stage cancers, treatment-related morbidities, and mortality.
- 6 February 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (6) , 1209-1217
Impact of screening for human papillomavirus-positive oropharyngeal cancers: a microsimulation-based modeling study
Background: We estimated the impact of screening on morbidity and mortality of human papillomavirus (HPV)16-positive oropharyngeal cancer among US men aged 45-79 years. Methods: We developed an individual-level, state-transition natural history microsimulation model to estimate the impact of screening using oral HPV16 detection, HPV16-E6 antibody detection, and transcervical ultrasound of neck/oropharynx. We compared clinical detection to counterfactual screen detection for cancer stage, single- vs multiple-modality treatment, and survival. Screening scenarios encompassed 4 progression speeds across cancer stages (very slow, slow, fast, and very fast) and 4 screening frequencies. Results: Among US men aged 45-79 years in 2021 (n = 54 881 311), 163 958 clinically diagnosed human papillomavirus (HPV)-positive oropharyngeal cancers and 32 009 deaths would occur through age 84 in the absence of screening. Assuming very-fast progression, 4%, 20%, 31%, and 60% of these cancers would be detected by one-off, 5-yearly, 3-yearly, and annual screening. Annual screening (very-fast progression) could reduce the number of cancers diagnosed at advanced stages (American Joint Committee on Cancer, 7th edition, stages III/IV: 90.0% with no screening vs 59.1%) and treated by multiple modalities (80.6% with no screening vs 50.6%). Cancer mortality would also be reduced by 36.2%, with a gain of 106 000 life-years. Annual screening would have a number needed to screen (NNS) of 561 per screen-detected cancer, 1118 per additional cancer treated by single modality, 4740 per death prevented, and 520 per life-year gained; such high NNS reflect potential inefficiency of population-level screening. Conclusions: If proven efficacious in randomized trials and cost-effective, screening for HPV-positive oropharyngeal cancers could provide considerable population-level reductions in advanced stage cancers, treatment-related morbidities, and mortality.
- Open Access
- 1 October 2024
- Published by Oxford University Press (OUP) in JNCI Monographs
- Vol. 2024 (67) , 417-423
A cervical cancer control strategy for lower-resource settings: interventions to complement one-dose HPV vaccination
One-dose prophylactic HPV vaccination of pre-adolescents may reduce cervical cancer deaths dramatically in lower-resource settings, but the benefits of achieving immediate high coverage among pre-adolescents would not be realized for 20 to 40 years. Prophylactic vaccine efficacy is reduced after sexual debut, and current therapeutic intervention candidates designed to treat existing HPV infections or precancerous lesions have yielded insufficient evidence to warrant widespread use. However, we are developing a feasible, scalable, high-quality cervical screening approach that could prevent hundreds of thousands of deaths, while we work to achieve high coverage of one-dose vaccination for adolescent cohorts. A time-limited “one screen” campaign approach for lower-resource settings could complement parallel efforts to achieve high coverage with one-dose vaccination. This screen-triage-treat strategy would target the highest risk groups of screening age (ie, 25 to 49 years) for once-in-a-lifetime HPV testing of self-collected samples using a low-cost accurate HPV test; subsequent triage relying on extended genotyping and a validated deep-learning algorithm for automated visual evaluation (AVE) would stratify management based on risk to provide treatment for those most likely to develop cancer without overburdening health care systems. Early efficacy of this approach has been demonstrated in 9 countries within the HPV-AVE (PAVE) Study Consortium. We estimate that the cost per death averted of a screen-triage-treat campaign is of similar magnitude to prophylactic vaccination. We do not envision perpetual investment in ubiquitous brick-and-mortar screening programs if “one dose, one screen” is implemented with high coverage and targets the highest-risk populations. In collaboration with in-country stakeholders, efforts to ensure acceptability, risk communication, and cost-effectiveness are underway.
- 1 October 2024
- Published by Oxford University Press (OUP) in JNCI Monographs
- Vol. 2024 (67) , 417-423
Open AccessA cervical cancer control strategy for lower-resource settings: interventions to complement one-dose HPV vaccination
One-dose prophylactic HPV vaccination of pre-adolescents may reduce cervical cancer deaths dramatically in lower-resource settings, but the benefits of achieving immediate high coverage among pre-adolescents would not be realized for 20 to 40 years. Prophylactic vaccine efficacy is reduced after sexual debut, and current therapeutic intervention candidates designed to treat existing HPV infections or precancerous lesions have yielded insufficient evidence to warrant widespread use. However, we are developing a feasible, scalable, high-quality cervical screening approach that could prevent hundreds of thousands of deaths, while we work to achieve high coverage of one-dose vaccination for adolescent cohorts. A time-limited “one screen” campaign approach for lower-resource settings could complement parallel efforts to achieve high coverage with one-dose vaccination. This screen-triage-treat strategy would target the highest risk groups of screening age (ie, 25 to 49 years) for once-in-a-lifetime HPV testing of self-collected samples using a low-cost accurate HPV test; subsequent triage relying on extended genotyping and a validated deep-learning algorithm for automated visual evaluation (AVE) would stratify management based on risk to provide treatment for those most likely to develop cancer without overburdening health care systems. Early efficacy of this approach has been demonstrated in 9 countries within the HPV-AVE (PAVE) Study Consortium. We estimate that the cost per death averted of a screen-triage-treat campaign is of similar magnitude to prophylactic vaccination. We do not envision perpetual investment in ubiquitous brick-and-mortar screening programs if “one dose, one screen” is implemented with high coverage and targets the highest-risk populations. In collaboration with in-country stakeholders, efforts to ensure acceptability, risk communication, and cost-effectiveness are underway.
- Open Access
- 1 November 2023
- Published by Oxford University Press (OUP) in JNCI Monographs
- Vol. 2023 (62) , 188-195
Adapting a model of cervical carcinogenesis to self-identified Black women to evaluate racial disparities in the United States
Background: Self-identified Black women in the United States have higher cervical cancer incidence and mortality than the general population, but these differences have not been clearly attributed across described cancer care inequities. Methods: A previously established microsimulation model of cervical cancer was adapted to reflect demographic, screening, and survival data for Black US women and compared with a model reflecting data for all US women. Each model input with stratified data (all-cause mortality, hysterectomy rates, screening frequency, screening modality, follow-up, and cancer survival) was sequentially replaced with Black-race specific data to arrive at a fully specified model reflecting Black women. At each step, we estimated the relative contribution of inputs to observed disparities. Results: Estimated (hysterectomy-adjusted) cervical cancer incidence was 8.6 per 100 000 in the all-race model vs 10.8 per 100 000 in the Black-race model (relative risk [RR] = 1.24, range = 1.23-1.27). Estimated all-race cervical cancer mortality was 2.9 per 100 000 vs 5.5 per 100 000 in the Black-race model (RR = 1.92, range = 1.85-2.00). We found the largest contributors of incidence disparities were follow-up from positive screening results (47.3% of the total disparity) and screening frequency (32.7%). For mortality disparities, the largest contributor was cancer survival differences (70.1%) followed by screening follow-up (12.7%). Conclusion: To reduce disparities in cervical cancer incidence and mortality, it is important to understand and address differences in care access and quality across the continuum of care. Focusing on the practices and policies that drive differences in treatment and follow-up from cervical abnormalities may have the highest impact.
- 1 November 2023
- Published by Oxford University Press (OUP) in JNCI Monographs
- Vol. 2023 (62) , 188-195
Open AccessAdapting a model of cervical carcinogenesis to self-identified Black women to evaluate racial disparities in the United States
Background: Self-identified Black women in the United States have higher cervical cancer incidence and mortality than the general population, but these differences have not been clearly attributed across described cancer care inequities. Methods: A previously established microsimulation model of cervical cancer was adapted to reflect demographic, screening, and survival data for Black US women and compared with a model reflecting data for all US women. Each model input with stratified data (all-cause mortality, hysterectomy rates, screening frequency, screening modality, follow-up, and cancer survival) was sequentially replaced with Black-race specific data to arrive at a fully specified model reflecting Black women. At each step, we estimated the relative contribution of inputs to observed disparities. Results: Estimated (hysterectomy-adjusted) cervical cancer incidence was 8.6 per 100 000 in the all-race model vs 10.8 per 100 000 in the Black-race model (relative risk [RR] = 1.24, range = 1.23-1.27). Estimated all-race cervical cancer mortality was 2.9 per 100 000 vs 5.5 per 100 000 in the Black-race model (RR = 1.92, range = 1.85-2.00). We found the largest contributors of incidence disparities were follow-up from positive screening results (47.3% of the total disparity) and screening frequency (32.7%). For mortality disparities, the largest contributor was cancer survival differences (70.1%) followed by screening follow-up (12.7%). Conclusion: To reduce disparities in cervical cancer incidence and mortality, it is important to understand and address differences in care access and quality across the continuum of care. Focusing on the practices and policies that drive differences in treatment and follow-up from cervical abnormalities may have the highest impact.
- Open Access
- 8 May 2023
- Published by American Association for Cancer Research (AACR)
Data from Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047
On February 2, 2022, President Biden and First Lady Dr. Biden reignited the Cancer Moonshot, setting a new goal to reduce age-standardized cancer mortality rates by at least 50% over the next 25 years in the United States. We estimated trends in U.S. cancer mortality during 2000 to 2019 for all cancers and the six leading types (lung, colorectum, pancreas, breast, prostate, liver). Cancer death rates overall declined by 1.4% per year from 2000 to 2015, accelerating to 2.3% per year during 2016 to 2019, driven by strong declines in lung cancer mortality (−4.7%/year, 2014 to 2019). Recent declines in colorectal (−2.0%/year, 2010–2019) and breast cancer death rates (−1.2%/year, 2013–2019) also contributed. However, trends for other cancer types were less promising. To achieve the Moonshot goal, progress against lung, colorectal, and breast cancer deaths needs to be maintained and/or accelerated, and new strategies for prostate, liver, pancreatic, and other cancers are needed. We reviewed opportunities to prevent, detect, and treat these common cancers that could further reduce population-level cancer death rates and also reduce disparities.Significance:We reviewed opportunities to prevent, detect, and treat common cancers, and show that to achieve the Moonshot goal, progress against lung, colorectal, and breast cancer deaths needs to be maintained and/or accelerated, and new strategies for prostate, liver, pancreatic, and other cancers are needed.See related commentary by Bertagnolli et al., p. 1049.This article is highlighted in the In This Issue feature, p. 1027
- 8 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047
On February 2, 2022, President Biden and First Lady Dr. Biden reignited the Cancer Moonshot, setting a new goal to reduce age-standardized cancer mortality rates by at least 50% over the next 25 years in the United States. We estimated trends in U.S. cancer mortality during 2000 to 2019 for all cancers and the six leading types (lung, colorectum, pancreas, breast, prostate, liver). Cancer death rates overall declined by 1.4% per year from 2000 to 2015, accelerating to 2.3% per year during 2016 to 2019, driven by strong declines in lung cancer mortality (−4.7%/year, 2014 to 2019). Recent declines in colorectal (−2.0%/year, 2010–2019) and breast cancer death rates (−1.2%/year, 2013–2019) also contributed. However, trends for other cancer types were less promising. To achieve the Moonshot goal, progress against lung, colorectal, and breast cancer deaths needs to be maintained and/or accelerated, and new strategies for prostate, liver, pancreatic, and other cancers are needed. We reviewed opportunities to prevent, detect, and treat these common cancers that could further reduce population-level cancer death rates and also reduce disparities.Significance:We reviewed opportunities to prevent, detect, and treat common cancers, and show that to achieve the Moonshot goal, progress against lung, colorectal, and breast cancer deaths needs to be maintained and/or accelerated, and new strategies for prostate, liver, pancreatic, and other cancers are needed.See related commentary by Bertagnolli et al., p. 1049.This article is highlighted in the In This Issue feature, p. 1027
- Open Access
- 8 May 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S11 and Figure S1 from Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047
Supplemental Table 1. 15 leading causes of cancer death in the U.S. in 2019. Supplemental table 2. Trends in total cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 3. Trends in lung cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 4. Trends in colorectal cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 5. Trends in pancreatic cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 6. Trends in female breast cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 7. Trends in prostate cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 8. Trends in liver/IHBD cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 9. Trends in cancer mortality rates in the U.S., 2000-2019 for selected sites. Supplemental Table 10. US breast cancer incidence-based mortality*. Supplemental Table 11. U.S. breast cancer incidence-based mortality by age at death. Supplemental Figure 1. Liver cancer incidence (1992-2019), survival (2000-2019) and mortality (2000-2019 projected through 2047). This figure excludes cases of intrahepatic bile duct cancer.
- 8 May 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S11 and Figure S1 from Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047
Supplemental Table 1. 15 leading causes of cancer death in the U.S. in 2019. Supplemental table 2. Trends in total cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 3. Trends in lung cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 4. Trends in colorectal cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 5. Trends in pancreatic cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 6. Trends in female breast cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 7. Trends in prostate cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 8. Trends in liver/IHBD cancer mortality rates, incidence rates and relative survival in the U.S. Supplemental table 9. Trends in cancer mortality rates in the U.S., 2000-2019 for selected sites. Supplemental Table 10. US breast cancer incidence-based mortality*. Supplemental Table 11. U.S. breast cancer incidence-based mortality by age at death. Supplemental Figure 1. Liver cancer incidence (1992-2019), survival (2000-2019) and mortality (2000-2019 projected through 2047). This figure excludes cases of intrahepatic bile duct cancer.